Partner Network

Key positioning: "The turn-key solution for rare disease marketers." The EQ5 + RMN partnership is the only offering that combines 100% deterministic NPI-level social targeting (EQ5) with a rare disease-specific content environment (RMN). No competitor offers this as a single integrated platform. EQ5 earns 70% gross margin on all RMN placements. Three-month minimum commitment on all products.

How EQ5 uses PurpleLab: PurpleLab's real-world claims data and HCP audience infrastructure complements EQ5's Personi-5™ NPI targeting by providing claims-derived enrichment signals. This allows EQ5 to layer prescribing behavior and treatment patterns onto social targeting — improving audience quality and enabling pharma clients to reach the highest-value prescribers. Source: PurpleLab Overview, April 2026.

Sales positioning: IQM's monthly target list optimization is a differentiated value-add that positions EQ5 campaigns as intelligent and self-improving — unlike competitors who deliver a static campaign and report at the end. This directly addresses a common pharma buyer objection: "What happens after launch?" With IQM integration, EQ5 can show that every campaign learns and improves month-over-month using real engagement data at the physician level.

Sales positioning: OptimizeRx adds the one channel EQ5 can't reach on its own — the EHR at the point of care. Where EQ5 delivers 100% deterministic NPI-level social and programmatic targeting, OptimizeRx reinforces that same physician inside the clinical workflow at the moment of prescribing, and extends the program to the patient through synced DTC. For brand teams asking "how do we reach the HCP when it matters most?", the EQ5 + OptimizeRx pairing covers both the awareness moment (social/programmatic) and the decision moment (EHR point-of-care). Source: optimizerx.com, May 2026.

Sales positioning: Talkwalker is the macro-sentiment layer EQ5 can offer alongside its NPI-level activation. For brand teams asking "what does the HCP and patient conversation actually look like?" we now have an answer with structured AI segmentation, DOL mapping, and live dashboards — not just an opinion. Lead with the live GLP-1 demo dashboard in any conversation where macro market intelligence is on the table (Novo, Lilly, Amgen MariTide, and any cardiometabolic/obesity launch).

Status: Demo phase complete with the Hootsuite/Talkwalker team. Consumption-based pricing scoping conversation in progress; Amgen opportunity being scoped as a separate engagement. Compliance files available at the Hootsuite Trust Center.

Sales positioning: Healthlink Dimensions closes the offline gap in EQ5's omnichannel story. For brand teams running coordinated HCP programs, pairing EQ5's deterministic NPI-level digital targeting with Healthlink's verified direct mail reach means the same physician sees consistent messaging in their feed AND in their office — reinforcing frequency across channels without duplicating cost. Source: healthlinkdimensions.com.

Sales positioning: InsightRx extends EQ5's reach into the precision dosing workflow — a channel where high-complexity specialty prescribers (oncology, nephrology, ID, transplant) are actively engaged with the brand's therapeutic area. For pharma brands with complex dosing regimens, combining EQ5's NPI-level awareness targeting with InsightRx's clinical decision support presence creates a rare opportunity to influence the HCP across both the awareness journey and the active prescribing moment. Source: insightsrx.ai.

Sales positioning: Pulse Health adds the triggered email layer that turns EQ5's NPI-level ad engagement into an automated follow-up sequence — without requiring a rep to manually send. When an HCP clicks an EQ5 ad, Pulse fires a personalized email within the same session window, extending the moment of interest into a nurtured journey. For pharma brand teams asking "what happens after the click?", this is the answer: a CRM purpose-built for life science that closes the loop between paid media engagement and direct HCP communication. Source: Pulse Health Engagement Cloud 2026.